Physician profile
Morton Glaser
NPI 1487657755
$3,039.79
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $1,219 · 2021: $52.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $627.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $558.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $279.48 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $174.62 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $149.91 | 2019-2020 | |
| Mylan Specialty L.P. | $121.21 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $116.62 | 2020 | |
| Electromed, INC. | $102.87 | 2019 | |
| Merck Sharp & Dohme LLC | $102.81 | 2019-2020 | |
| Advanced Respiratory, INC | $96.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $94.19 | 2019-2020 | |
| Genentech USA, INC. | $77.26 | 2019 | |
| Mallinckrodt Enterprises LLC | $69.26 | 2019 | |
| Allergan, INC. | $58.82 | 2019-2020 | |
| Chiesi USA, INC. | $57.21 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $56.99 | 2019 | |
| Vapotherm INC | $42.43 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $33.63 | 2020 | |
| La Jolla Pharmaceutical Company | $30.41 | 2020 | |
| Optinose US, INC. | $21.55 | 2019 | |
| United Therapeutics Corporation | $20.58 | 2021 | |
| Grifols USA, LLC | $20.56 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.88 | 2020 | |
| Apria Healthcare LLC | $19.53 | 2021 | |
| Boston Scientific Corporation | $19.12 | 2020 | |
| Pfizer INC. | $15.70 | 2019 | |
| Olympus America INC. | $15.08 | 2020 | |
| Philips North America LLC | $14.51 | 2019 | |
| Medtronic USA, INC. | $12.16 | 2020 | |
| Medtronic, INC. | $11.97 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morton Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.